Effect of cinnamon in the treatment of Helicobacter Pylori

Comparison of the efficacy of addition of Cinnamon powder and placebo in eradication of Helicobacter Pylori infection, a clinical trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201505032276N2

Enrollment

152

Registered

2015-08-01

Start date

2015-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

helicobacter pylori B98.0. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters

Interventions

Intervention 1: Intervention group: clarithromycin 500 mg BD+ amoxicillin 1g BD+ omeprazole 20 mg BD + 400 mg Cinnamon powder in capsules BD for two weeks. (oral). Intervention 2: Control group: clar

Treatment - Drugs

Intervention group: clarithromycin 500 mg BD+ amoxicillin 1g BD+ omeprazole 20 mg BD + 400 mg Cinnamon powder in capsules BD for two weeks. (oral)

Control group: clarithromycin 500 mg BD+ amoxicillin 500 mg BD+ omeprazole 20 mg BD + placebo capsules appeared quite similar to Cinnamon capsules (twise daily) for two weeks. (oral)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with dyspepsia; nosea; vomiting; epigastric pain attending gastrointestinal clinic of Velayat hospital and infectious diseases clinic of Bualisina hospital with positive evidense of Helicobacter Pylori infection (stool antigen test). Exclusion criteria: HIV infection; known cases of malignancies.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Negative result of stool antigen of Helicobacter Pylori. Timepoint: 6 weeks after the end of treatment. Method of measurement: Checking of H.Pylori stool antigen.	—

Secondary

Measure	Time frame
Oral ulcer. Timepoint: During, end and till 6 weeks after end of treatment. Method of measurement: Patient report.;Epigasteric pain. Timepoint: During, end and till 6 weeks after end of treatment. Method of measurement: Patient report.;Skin rash. Timepoint: During, end and till 6 weeks after end of treatment. Method of measurement: Patient report.;Diarrhea. Timepoint: During, end and till 6 weeks after end of treatment. Method of measurement: Patient report.	—

Measure

Time frame

Oral ulcer. Timepoint: During, end and till 6 weeks after end of treatment. Method of measurement: Patient report.;Epigasteric pain. Timepoint: During, end and till 6 weeks after end of treatment. Method of measurement: Patient report.;Skin rash. Timepoint: During, end and till 6 weeks after end of treatment. Method of measurement: Patient report.;Diarrhea. Timepoint: During, end and till 6 weeks after end of treatment. Method of measurement: Patient report.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Homayuni

Qazvin University of Medical Sciences and health Servises

homauni.h@gmail.com+98 28 3333 2930

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026